Interstitial transfer factor as adjuvant immunotherapy for experimental glioma

Journal of Experimental and Clinical Cancer Research

Volumn 24, Issue 4, 2005, Pages 575-583

  Pineda, Benjamin ^a,b   Estrada Parra, S ^b   Pedraza Medina, B ^b   Rodriguez Ropon, A ^b   Perez R ^a   Arrieta, O ^a  

^a NATIONAL INSTITUTE OF NEUROLOGY AND NEUROSURGERY   (Mexico)

^b INSTITUTO POLITÉCNICO NACIONAL   (Mexico)

Author keywords

Glioma; Immunotherapy; Transfer Factor

Indexed keywords

CARMUSTINE; CD2 ANTIGEN; CD4 ANTIGEN; CD8 ANTIGEN; CREATININE; CYTOKINE; GAMMA INTERFERON; GLUCOSE; IMMUNE TRANSFER FACTOR; INTERLEUKIN 10; INTERLEUKIN 2; INTERLEUKIN 6; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MESSENGER RNA; MONOCYTE CHEMOTACTIC PROTEIN 1; NITROGEN; TUMOR NECROSIS FACTOR ALPHA; UREA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BLOOD CELL COUNT; BLOOD CHEMISTRY; CANCER IMMUNOTHERAPY; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOKINE RELEASE; DELAYED HYPERSENSITIVITY; DOSE RESPONSE; DRUG POTENTIATION; DRUG TOXICITY; FEMALE; FLOW CYTOMETRY; GLIOBLASTOMA; GLIOMA CELL; HISTOPATHOLOGY; LEUKOCYTE COUNT; LIVER FUNCTION TEST; LYMPHOCYTE COUNT; MALE; MORTALITY; NATURAL KILLER CELL; NONHUMAN; PRIORITY JOURNAL; PROGNOSIS; RAT; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SWINE; TUMOR VOLUME; WEIGHT REDUCTION;

ANIMALS; ANTINEOPLASTIC AGENTS, ALKYLATING; APOPTOSIS; BRAIN NEOPLASMS; CARMUSTINE; CELL LINE, TUMOR; CYTOKINES; DISEASE MODELS, ANIMAL; FLOW CYTOMETRY; GLIOMA; IMMUNOTHERAPY; KILLER CELLS, NATURAL; RATS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; T-LYMPHOCYTES; TRANSFER FACTOR;

EID: 31344463427     PISSN: 03929078     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (36)

1. Rozzo S.J., Kirpatrick C.H.: Purification of transfer factor. Mol. Inmunol. 29:167-182, 1992.
2. Alvarez-Thull L., Kirkpatrick C.H.: Profiles of cytokine production in recipients of transfer factors. Biotherapy 9:55-59, 1996.
3. Fahre R.A., Perez T.M., Aguilar L.D., Rangel M.J., Estrada-Garcia I., Hernandez-Pando R., Estrada Parra S.: Transfer factors as immunotherapy and supplement of chemotherapy in experimental pulmonary tuberculosis. Clin. Exp. Immunol. 136:215-223, 2004.
4. Karhumaki E., Marnela K.M., Krohn K.: Chromatographic and enzymatic effects on transfer factor-like activity from human leukocytes and porcine spleen dialysate. Int. J. Biochem. 20:1067-1072, 1988.
5. Gottlieb A.A., Maziarz G.A., Tamaki N., Sutcliffe S.B.: The effects of dialyzable products from human leukocyte extracts on cutaneous delayed-hypersensitivity response. J. Immunol. 124:885-892, 1980.
6. Pizza G., DeVinci C., Fudenberg H.H.: Transfer factor in malignancy. Progress in Drug Research 42:401-420, 1993.
7. Kirkpatrick C.H., Gallin J.I.: Treatment of infectious and neoplastic diseases with transfer factor. Oncology 29:46-73, 1974.
8. Lopez-Gonzalez M.A., Sotelo J.: Brain tumors in Mexico: characteristics and prognosis of glioblastoma. Surg. Neurol. 53:157-162, 2000.
9. Arrieta O., Garcia E., Guevara P., Garcia-Navarrete R., Ondarza R., Rembao D., Sotelo J.: Hepatocyte growth factor is associated with poor prognosis of malignant gliomas and is a predictor for recurrence of meningioma. Cancer 94:3210-3218, 2002.
10. Sotelo J., Guevara P., Reyes S., Arrieta O.: Interstitial quinacrine for elimination of abnormal tissue; therapy of experimental glioma. Surgery 128:439-446, 2000.
11. Ehtesham M., Black K.L., Yu J.S.: Recent progress in immunotherapy for malignant glioma: treatment strategies and results from clinical trials. Cancer Control 11:192-207, 2004.
12. Benda P., Lightbody J., Sato G., Levine L., Sweet W.: Differentiated Rat Glial Cell Strain in Tissue Culture. Science 161: 370-371, 1968.
13. Arrieta O., Guevara P., Reyes S., Ortiz A., Rembao D., Sotelo J.: Protamine inhibits angiogenesis and growth of C6 rat Glioma; a synergistic effect when combined with carmustine. Eur. J. Cancer 34:2101-2106, 1998.
14. Tomayko M.M., Reynolds P.C.: Determination of subcutaneous tumor size in athymic (nude) mice. Cancer Chemother. Pharmacol. 24:148-154, 1989.
15. Walker K.B., Butler R., Colston M.J.: Role of Th-1 lymphocytes in the development of protective immunity against Mycobacterium leprae. J. Immunol. 148:1885-1889, 1992.
16. Dix A.R., Brooks W., Rozzman T.L., Morford M.A.: Immune defects observed in patients with primary malignant brain tumors. J. Neuroimmunolog. 100:216-232, 1999.
17. Elliott L.H., Brooks W.H., Roszman T.L., Dudka L., Skaggs C.: Citokinetic basis for the impaired activation of limphocytes from patients with primary intracranial tumors. J. Immunol. 132:1208-1216, 1984.
18. Morford L.A., Elliott L.H., Carlson S.L., Brooks W.H., Roszman T.L.: T cell receptor-mediated signaling is defective in T cells obtained from patients with primary intracranial tumors. J. Immunol. 159:4415-4425, 1997.
19. Reyes S., Herrera L.A., Ostrosky P., Sotelo J.: Quinacrine enhances carmustine therapy of experimental rat glioma. Neurosurgery 49:969-973, 2001.
20. Fudenberg H.H., Pizza G.: Transfer Factor.: New frontiers. Prog. Drug. Res. 42:309-400, 1993.
21. Estrada-Parra S., Chavez-Sanchez R., Ondarza-Aguilera R., et al.: Immunotherapy with transfer factor of recurrent herpes simplex type I. Arch. Med. Res.; 26 Spec No:S87-92, 1995.
22. Estrada-Parra S., Nagaya A., Serrano E., et al.: Comparative study of transfer factor and acyclovir in the treatment of herpes zoster. Int. J. Immunopharmacol. 20:521-535, 1998.
23. Wilson G.B., Poindexter C., Fort J.D., Ludden K.D.: De novo initiation of specific cell-mediated immune responsiveness in chickens by transfer factor (specific immunity inducer) obtain from bovine colostrums and milk. Acta Virol. 32:6-18, 1988.
24. Pizza G., de Vinci C., Viza D.: Immunotherapeutic approaches for renal cancer. Folia Biol. (Praha). 48:167-181, 2002.
25. Pilotti V., Mastrorilli M., Pizza G. et al.: Transfer factor as an adjuvant to non-small cell lung cancer (NSCLC) therapy. Biotherapy 9:117-121, 1996.
26. Barth R.F.: Rat brain tumor model in experimental neurooncology: the 9L, C6, T9, F98, R62, (D74), RT2 and CNS01, gliomas. J. Neurooncol. 36:91-102, 1998.
27. Carlomagno C., Perrone F., Lauria R., et al.: Prognostic significance of necrosis, elastosis, fibrosis and inflammatory cell reaction in operable breast cancer. Oncology 52:272-277, 1995.
28. Zhang L., Conejo-Garcia J.R., Katsaros D. et al.: Intratumoral T Cells, Recurrence, and Survival in Epithelial Ovarian Cancer. N. Engl. J. Med. 348:203-213, 2003.
29. Fukushima T., Yamamoto M., Oshiro S., Tsugu H., Hirakawa K., Soma G.: Recombinant mutant human tumor necrosis factor-alpha (TNF-SAM2) immunotherapy with ranimustine chemotherapy and concurrent radiation therapy for malignant astrocytomas. Anticancer Res. 23:4473-4481, 2003.
30. Goetz C., Rachinger W., Poepperl G. et al.: Intralesional radioimmunotherapy in the treatment of malignant glioma: clinical and experimental findings. Acta Neurochir. Suppl. 88:69-75, 2003.
31. Roszman T.L., Brooks W.H., Steele C., Elliott L.H.: Pokeweed mitogen-induced immunoglobulin secretion by peripheral blood lymphocytes from patients with primary intracranial tumors. Characterization of T helper and B cell function. J. Immunol. 134:1545-1550, 1985.
32. Apuzzo M.L., Mitchell M.S.: Immunological aspects of intrinsic glial tumors. J. Neurosurg. 55:1-18, 1981.
33. Yoshida S., Takai N., Tanaka R.: Functional analysis of interleukin-2 in immune surveillance against brain tumors. Neurosurgery 21:627-630, 1987.
34. Chen G.G., Chak E.C., Chun Y.S., Lam I.K., Sin F.L., Leung B.C., Ng H.K., Poon W.S.: Glioma apoptosis induced by macrophages involves both death receptor-dependent and independent pathways. J. Lab. Clin. Med. 141:190-199, 2003.
35. Fujita H., Koji T., Kitagawa N., Tsutsumi K., Abe K., Kaminogo M., Shibata S.: Possible involvement of Fas system in the induction of apoptosis in human astrocytic brain tumors. Cell. Mol. Neurobiol. 22:393-406, 2002.
36. Kuriyama H., Lamborn K.R., O'Fallon J.R. et al.: Prognostic significance of an apoptotic index and apoptosis/proliferation ratio for patients with high-grade astrocytomas. Neuro-oncol. 4:179-186, 2002.